# Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

> **NCT02222155** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 42 (actual)

## Conditions studied

- ANCA-associated Vasculitis

## Interventions

- **DRUG:** CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
- **DRUG:** CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
- **OTHER:** Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids

## Key facts

- **NCT ID:** NCT02222155
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-04
- **Primary completion:** 2016-04-24
- **Final completion:** 2016-07-19
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222155, "Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02222155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*